1259305-29-7

Aripiprazole lauroxil is a long acting injectable (LAI) pro-drug formulation of aripiprazole approved in the U.S. for the treatment of schizophrenia. Aripiprazole lauroxil is a dopamine D2 receptor partial antagonist, a 5-HT2A antagonist, and a 5- HT1A partial agonist that was developed by Alkermes. It was Aripiprazole lauroxil is a long acting injectable (LAI) pro-drug formulation of aripiprazole approved in the U.S. for the treatment of schizophrenia.28 Aripiprazole lauroxil is a dopamine D2 receptor partial antagonist, a 5-HT2A antagonist, and a 5- HT1A partial agonist that was developed by Alkermes. It was

ChEBI: A dodecanoate ester obtained by formal condensation of the carboxy group of dodecanoic acid with the hydroxy group of 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-2-oxo-3,4-dihydroquinolin-1(2H)-yl]methanol. A prodrug for aripipraz le, it is used for treatment of schizophrenia.

The synthesis of aripiprazole lauroxil has only been described on gram scale in the patent literature. Commercially available aripiprazole (58) was treated with formaldehyde to give hemiaminal 59 in 65% crude yield and was then heated with lauric anhydride to give aripiprazole lauroxil (VII) in 21% overall yield.